-67.7%
ADBE vs MRNA
-27.3%
-40.4%
-71.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.8% | -2.2% | +0.4% | -1.7% |
| 7D | -10.4% | -12.7% | +2.3% | -9.8% |
| 30D | -14.6% | -20.7% | +6.0% | -13.8% |
| 3M | -20.0% | +46.3% | -66.3% | -22.3% |
| 6M | -14.1% | +305.2% | -319.3% | -27.3% |
| YTD | -37.8% | +561.2% | -599.0% | -51.7% |
| 1Y | -30.3% | +772.1% | -802.4% | -48.3% |
| 3Y | -64.5% | +147.0% | -211.4% | -70.6% |
| All | -67.7% | -27.3% | -40.4% | -69.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling